Short answer
Fulgent Genetics, Inc. (FLGT) filed its Q3 2025 10-Q quarterly report on Nov 7, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $84M (up 17.2% year over year) with net income of −$7M.
Q3 2025 key financials · XBRL
- Revenue
- $84M
- +17.2% YoY · +2.8% QoQ
- Net income
- −$7M
- +54.9% YoY · +65.1% QoQ
- Operating margin
- -18.3%
- Gross margin
- 42.2%
Source: XBRL data from the Fulgent Genetics, Inc. (FLGT) Q3 2025 10-Q on SEC EDGAR. USD.
Fulgent Genetics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $84.1M, up 17% from $71.7M YoY
- Gross margin 42% vs 37% YoY; operating loss $15.4M vs $17.1M
- Best performer BioPharma services revenue $7.2M, up 83%; weakest COVID-19 revenue $0
- Cash and securities $787.7M vs $828.6M at December 31, 2024
- Nine-month operating cash use $23.5M vs $4.0M; $10.9M stock repurchases
- Outlook: higher clinical-trial spending and cash use; IRS refund expectation $106.7M potentially delayed by shutdown
Risk Factors
- Filing text contains no Risk Factors section or stated changes from the 10-K
- ANP acquisition contingent consideration requiring up to 292,682 common shares upon cash-receipt milestones
- $267.9 million of equity proceeds used for operations and business combinations
- $139.6 million remaining under the stock repurchase authorization as of September 30, 2025
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Fulgent Genetics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.